Biochemical Markers of Atherosclerosis

Open access

Biochemical Markers of Atherosclerosis

This paper is a brief review of some lipid parameters and serum markers of inflammation in a view of their predictive relevance for the atherosclerotic disease. A discourse on the importance of measuring different lipids and lipoproteins, concentration of LDL particles and apolipoprotein levels is still underway. Also, the recommendations for apolipoprotein (a), phenotypization and other lipid markers have not yet been established. In recent years the recommendations imply simultaneous measuring of multiple markers and calculating the lipid index values such as lipid tetrad index (LTI), lipid pentad index (LPI) and atherogenic index of plasma (AIP). Several circulating markers of inflammation such as C-reactive protein, serum fibrinogen and elevated leukocyte number, are consistently associated with atherosclerosis. In spite of a lack of evidence on measuring the C-reactive protein in a wide population, the guidelines for its application in diagnostics and therapy of coronary heart disease were developed. Some proinflammatory cytokines, adhesion molecules and markers of leukocyte activation are promising markers, requiring, however, more detailed prospective evaluation. The question to be elucidated is if these inflammatory markers are directly involved in the pathogenic process.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Vukomirović ed. Statistical Yearbook of Serbia 2005. Belgrade Serbia SCG: Statistical Office of the Republic of Serbia; 2005. p. 90.

  • The Expert Panel. The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 2002; 106: 3143-421.

  • De Backer G Ambrosioni E Borch-Johnsen K. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-10.

  • Das B Daga MK Gupta SK. Lipid Pentad Index: A novel bioindex for evaluation of lipid risk factors for atherosclerosis in young adolescents and children of premature coronary artery disease patients in India. Clin Bioch 2007; 40 (1-2): 18-24.

  • Bogavac-Stanojević N Jelić-Ivanović Z Spasojević-Kalimanovska V Spasić S Kalimanovska-Oštrić D. Lipid and inflammatory markers for the prediction of coronary artery disease: A multi-marker approach. Clin Biochem 2007; 40 (13-14): 1000-6.

  • Kondo K Kitagawa K Nagai Y Yamagami H Hashimoto H Hougaku H et al. Associations of soluble adhesion molecule-1 with carotid atherosclerosis progression. Atherosclerosis 2005; 179 (1): 155-60.

  • Lind L. Circulating markers of inflamation and atherosclerosis. Atherosclerosis 2003; 169 (2): 203-14.

  • Koenig W. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein. Internat J Cardiol 2005; 98 (2): 199-206.

  • Wilson AM Ryan MC Boyle AJ. The novel role of C-reactive protein in cardiovascular disease: Risk marker or pathogen. Internat J Cardiol 2006; 106 (3): 291-7.

  • Paffen E De Maat MPM. C-reactive protein in atherosclerosis: A causal factor? Cardiovasc Res 2006; 71 (1): 30-9.

  • Pandolfi A. C-reactive protein: A potential new molecular link between inflammation thrombosis and vascular cell proliferation? Cardiovac Res 2005; 68 (1): 3-4.

  • Sacks FM. Apolipoprotein story. Atherosclerosis Suppl 2006; 7 (4): 23-7.

  • Chan DC Watts GF. Apolipoproteins as markers and managers of coronary risk. QJM 2006; 99 (5): 277-87.

  • Nakajima K Nakano T Tanaka A. The oxidative modification hypothesis of atherosclerosis: The comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta 2006; 367 (1-2): 36-47.

  • Rizzo M Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM 2006; 99 (1): 1-14.

  • Marcovina SM Albers JJ Henderson LO Hannon WH. International Federation of Clinical Chemistry standardization project for measurement of apolipoproteins A-I and B. III. Compatibility of apolipoprotein A-I values by use of international reference material. Clin Chem 1993; 39: 773-81.

  • Friedewald WT Levy RI Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 449-502.

  • Walldius G Junger I Holme I Aastveit AH Kolar W Steiner E. High apolipoprotein B low apolipoprotein A-1 and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.

  • Miller M Ginsberg HN Schaefer EJ. Relative Atherogenicity and Predictive Value of Non-High-Density Lipoprotein Cholesterol for Coronary Heart Disease. Am J Cardiol 2008; 101 (7): 1003-8.

  • Ballantyne C Arroll B Shepherd J. Lipids and CVD management: towards a global consensus. Eur Heart J 2005; 26 (21): 2224-31.

  • Dobiášova M Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoblipoprotein-depleted plasma (FERHDL). Clin Biochem 2001; 34 (7): 583-8.

  • Rajappa M Sridhar MG Balachander J Sethuraman KR. Lipoprotein (a) and comprehensive lipid tetrad index as a marker for coronary artery disease in NIDDM patients in South India. Clin Chim Acta 2006; 372 (1-2): 70-5.

  • Kushner I Rzewnicki D Samols D. What Does Minor Elevation of C-Reactive Protein Signify? Am J Med 2006; 119 (2): 166.e17-e28.

  • Ridker PM Rifai N Rose L Buring JE Cook NR. Comparison of C-reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events. N Engl J Med 2002; 347 (20): 1557-65.

  • Pearson TA Mensah GA Alexander RW Anderson JL Cannon RO III Criqui M et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.

  • Ignjatović S Majkić N. Biomarkers of diseases: An evidence-based approach. Jugoslov Med Biohem 2006; 25: 227-33.

  • Mendall MA Patel P Ballam L Strachan D Northfield TC. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312: 1061-5.

  • Kamath S Lip GYH. Fibrinogen: biochemistry epidemiology and determinants. Q J Med 2003; 96: 711-29.

  • Anderson JL Adams CD Antman EM Bridges CR Califf RM Casey DE Jr et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50 (7): e1-e157.

  • Braunwald E Antman EM Beasley JW Califf RM Cheitlin MD Hochmanet JS et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000; 36: 970-1062.

  • Francisco G Hernández C Simó R. Serum markers of vascular inflammation in dyslipemia. Clin Chim Acta 2006; 369 (1): 1-16.

  • Aristoteli LP Moller HJ Bailey B Moestrup SK Kritharides L. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 2006; 184 (2): 342-7.

  • Panteghini M. Biochemical markers of cardiac diseases. Jugoslov Med Biohem 2004; 23: 210-11.

  • Lazzerini PE Capecchi PL Selvi E Lorenzini S Bisogno S Galeazzi M et al. Hyperhomocysteinemia inflammation and autoimmunity. Autoimmunity Rev 2007; 6 (7): 503-9.

  • Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006; 189: 47-60.

Journal information
Impact Factor

IMPACT FACTOR 2018: 2,000
5-year IMPACT FACTOR: 1,075

CiteScore 2018: 1.47

SCImago Journal Rank (SJR) 2018: 0.523
Source Normalized Impact per Paper (SNIP) 2018: 0.581

Cited By
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 416 236 12
PDF Downloads 193 137 8